Bioactive plant chemicals are considered to be rich and useful for creating nanomaterials. The current work investigated the biosynthesis of silver nanoparticles (AgNPs) using ethanolic flaxseed extract as an efficient reducing factor. The production of AgNPs was verified by color-shifting observation of the mixture of silver nitrate (AgNO₃) from yellow to a reddish suspension after the addition of the extract and by evaluating it by UV–visible inspection. Additionally, FTIR spectrum was used to support the identification of functional groups. The morphology and structure of AgNPs were assessed using scanning electron microscopy (SEM), and X-ray diffraction (XRD) examinations, which revealed spherical AgNPs with a diameter of 46.98 ± 12.45 nm and a crystalline structure. The zeta potential (ZP) and dynamic light scattering (DLS) measurements of AgNPs revealed values of −44.5 mV and 231.8 nm, respectively, suggesting appropriate physical stability. The antibacterial activity of AgNPs was investigated against Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, and Streptococcus pyogenes, while the antioxidant effect was investigated using the DPPH technique. These obtained AgNPs could potentially be used as efficient antibacterial and antioxidant nanomaterials.

Coronavirus disease 19 (COVID-19) is an ongoing global pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The severity and mortality rates of COVID-19 are affected by several factors, such as respiratory diseases, diabetes, and hypertension. Bacterial coinfections are another factor that could contribute to the severity of COVID-19. Limited studies have investigated morbidity and mortality due to microbial coinfections in COVID-19 patients. Here, we retrospectively studied the effects of bacterial coinfections on intensive care unit (ICU)-admitted patients with COVID-19 in Asir province, Saudi Arabia. We analyzed electronic medical records of hospitalized patients with COVID-19 at Asir Central Hospital. A total of 34 patients were included, and the clinical data of 16 patients infected with SARS-CoV-2 only and 18 patients coinfected with SARS-CoV-2 and bacterial infections were analyzed in our study. Our data showed that the length of stay at the hospital for patients infected with both SARS-CoV-2 and bacterial infection was 35.2 days, compared to 16.2 days for patients infected with only SARS-CoV-2 (p = 0.0001). In addition, higher mortality rates were associated with patients in the coinfection group compared to the SARS-CoV-2-only infected group (50% vs. 18.7%, respectively). The study also showed that gram-negative bacteria are the most commonly isolated bacteria in COVID-19 patients. To conclude, this study found that individuals with COVID-19 who presented with bacterial infections are at higher risk for a longer stay at the hospital and potentially death. Further studies with a larger population are warranted to better understand the clinical outcomes of COVID-19 with bacterial infections.

Rauwolfia serpentina (R. serpentina), belonging to the family Apocynaceae, is a renowned medicinal herb for its different pharmacological activities such as antibacterial, antifungal, anti-inflammatory, and antiproliferative characteristics. This study has done a comparative assessment of the antibacterial, antioxidant, and anti-cancer activity of R. serpentina aqueous leaf extract (RSALE) with encapsulated gold nanoparticles (R-AuNPs). The R-AuNPs are prepared so that they are significant in size, monodispersed, and extremely stable. Their characterization was done by numerous parameters, including UV-visible spectroscopy (528 nm), transmission electron microscopy (~17 d. nm), dynamic light scattering (~68 d. nm), and zeta-potential (~−17 mV). Subsequently, a potent antibacterial activity was depicted via RSALE and R-AuNPs when examined by disc diffusion against various Gram-positive and Gram-negative bacterial strains. The obtained zones of inhibition of RSALE (100 mg/mL) were 34 ± 0.1, 35 ± 0.1, 28.4 ± 0.01, and 18 ± 0.01, although those of R-AuNPs (15 mg/mL) were 24.4 ± 0.12, 22 ± 0.07, 20 ± 0.16, and 17 ± 0.3 against Staphylococcus aureus (ATCC 25923), Escherichia coli (ATCC 25922), Bacillus subtilis (MTCC 8114), and Streptococcus pyogenes (ATCC 19615), respectively. However, no zone of inhibition was obtained when tested against Proteus vulgaris (MTCC 1771). Furthermore, the obtained MIC values for Staphylococcus aureus were 0.91, 0.61, and 1.15 mg/mL; for Escherichia coli, 0.79, 0.36, and 1.02 mg/mL; for Bacillus subtilis 0.42, 0.27, and 0.474 mg/mL; and for Streptococcus pyogenes, 7.67, 3.86, and 8.5 mg/mL of pure RSALE, R-AuNPs, and Amoxicillin (control), respectively, incorporating that R-AuNPs have been shown to have a 1.4-fold, 2.1-fold, 1.5-fold, and 1.9-fold enhanced antibacterial activity in contrast to pure RSALE tested against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, Streptococcus pyogenes, and Proteus vulgaris, respectively. Additionally, an enhanced antioxidant potential was detected in R-AuNPs compared to RSALE evaluated by the 2,2-Diphenyl-1-Picryl Hydrazyl Radical Scavenging (DPPH) Ferric reducing antioxidant power (FRAP) assay. The determined IC 50 values of RSALE and R-AuNPs were 0.131 ± 0.05 and 0.184 ± 0.02 mg/mL, and 0.110 ± 0.1 and 0.106 ± 0.24 mg/mL via the FRAP and DPPH assays, respectively. In addition, the anti-cancer activity against the human cervical cancer (Hela) cell line was evaluated, and the MTT assay results revealed that R-AuNPs (IC₅₀ 88.3 µg/mL) had an enhanced anti-cancer potential in contrast to RSALE (171.5 µg/mL). Subsequently, the findings of this study indicated that R. serpentina leaves and their nanoformulation can be used as a potent source for the treatment of the above-mentioned complications and can be used as a possible agent for novel target-based therapies for the management of different ailments.

Known for its high nutritional and medicinal value, okra (Abelmoschus esculentus) is commonly used for replacing plasma and expanding blood volume in humans. It is a major economic crop cultivated in tropical and subtropical regions worldwide. The present study aimed to investigate and evaluate the nutritional properties and prospective applications of the consumable parts of okra. The total ash content (mineral content), carbohydrate, crude fiber, fat, protein, and moisture fractions of okra pod aqueous extract were determined. The results show that okra aqueous extract contained 84.670–87.650% moisture, 1.514–1.197% ash, 7.857–8.261% carbohydrate, 2.367–3.410% crude protein, and 6.781–8.314% crude fiber. Okra was determined to have high nutritional value, with γ-tocopherol and α-tocopherol contents about 2.67 mg/100 g and 1.62 mg/100 g, respectively. High-performance liquid chromatography (HPLC) was performed to determine the sugars present in okra aqueous extract. The water-soluble polysaccharide content was 10.22–16.45 g/100 g. The tested aqueous extract was a rich source of total phenolic compounds in gallic acid equivalents (288.2–3426.2 mg/100 g), chlorophyll a (3.53 mg/100), chlorophyll b (2.43 mg/100), and carotenoids (1.3 mg/100 g). The detected minerals were Ca, Mg, Cu, Zn, Fe, K, Na, and Mn. Atomic absorption spectrometry analysis of these ashed minerals was performed. In addition to the nutritional benefits, okra pods exhibited antimicrobial, anticancer, and antioxidant properties. The aqueous extract was found to be potentially active against bacterial strains of Staphylococcus aureus (MIC value = 21.8 mg/mL), Escherichia coli (MIC value = 18.7 mg/mL), Bacillus cereus (MIC value = 20.7 mg/mL), and Klebsiella pneumoniae (MIC value = 20.2 mg/mL). Okra aqueous extract exhibited inhibitory activity against α-amylase (IC₅₀ = 120 µg/mL) and α-glucosidase (IC₅₀ = 115 µg/mL). The okra extract exhibited high anticancer activity, concentration-dependent and with an IC₅₀ value of about 158.3 mg/mL. The results indicated that okra pods have nutritional and medicinal properties and, hence, can be used as a functional food and broad-spectrum nutraceutical supplement.

The use of pharmaceuticals to treat Major Depressive Disorder (MDD) has several drawbacks, including severe side effects. Natural compounds with great efficacy and few side effects are in high demand due to the global rise in MDD and ineffective treatment. Yohimbine, a natural compound, has been used to treat various ailments, including neurological conditions, since ancient times. Serotonergic neurotransmission plays a crucial role in the pathogenesis of depression; thus, serotonergic receptor agonist/antagonistic drugs are promising anti-depressants. Yohimbine was investigated in this study to determine its antidepressant activity using molecular docking and pharmacokinetic analyses. Additionally, the in silico mutational study was carried out to understand the increase in therapeutic efficiency using site-directed mutagenesis. Conformational changes and fluctuations occurring during wild type and mutant serotonergic receptor, 5-hydroxytryptamine receptors 1A (5HT1A) and yohimbine were assessed by molecular dynamics MD simulation studies. Yohimbine was found to satisfy all the parameters for drug-likeness and pharmacokinetics analysis. It was found to possess a good dock score and hydrogen-bond interactions with wild type 5HT1A structure. Our findings elaborate the substantial efficacy of yohimbine against MDD; however, further bench work studies may be carried out to prove the same.

Minichromosome maintenance complex component 7 (MCM7) is involved in replicative licensing and the synthesis of DNA, and its overexpression is a fascinating biomarker for various cancer types. There is currently no effective agent that can prevent the development of cancer caused by the MCM7 protein. However, on the molecular level, inhibiting MCM7 lowers cancer-related cellular growth. With this purpose, this study screened 452 biogenic compounds extracted from the UEFS Natural Products dataset against MCM protein by using the in silico art of technique. The hit compounds UEFS99, UEFS137, and UEFS428 showed good binding with the MCM7 protein with binding energy values of −9.95, −8.92, and −8.71 kcal/mol, which was comparatively higher than that of the control compound ciprofloxacin (−6.50). The hit (UEFS99) with the minimum binding energy was picked for molecular dynamics (MD) simulation investigation, and it demonstrated stability at 30 ns. Computational prediction of physicochemical property evaluation revealed that these hits are non-toxic and have good drug-likeness features. It is suggested that hit compounds UEFS99, UEFS137, and UEFS428 pave the way for further bench work validation in novel inhibitor development against MCM7 to fight the cancers.